Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment

Travassos, Priscila Nunes Costa; Silva, Paulo Goberlânio de Barros; Freitas, Milena Oliveira; Braga, Marcus Davis Machado; Duarte, Fernando Barroso; Maia, Jéssica Karen de Oliveira; Pitombeira, Helena; Sousa, Jacqueline Holanda de; Alves, Ana Paula Negreiros Nunes

doi:10.1007/s00520-022-07159-3

Cited by 2 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Travasso et al. [ 22 ], on 75 patients with hematological malignancies receiving antineoplastic treatment, the prevalence of renal disorders was 52.4% according to the CKD-EPI equation. After treatment of chronic myeloid leukemia with imatinib, CKD developed in 16% [ 23 ], whereas in other studies, CKD was diagnosed after therapy with tyrosine kinase inhibitors (imatinib, dasatinib, and nilotinib) in 22%, 5%, and 4% respectively and in 14% in the whole population [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation

Kępska-Dzilińska,

Karakulska-Prystupiuk,

Kaszyńska

et al. 2023

Renal Failure

View full text Add to dashboard Cite

The hematopoietic stem cell transplantation (HSCT) is performed for various hematological diseases. Chronic kidney disease (CKD) occurs relatively often after HSCT. Anemia after HSCT may be due to CKD and/or other reasons. The aim of this study is to assess the prevalence of anemia and its possible relationship to the presence of CKD in patients at least 3 months after HSCT. The study included 156 patients who underwent allogeneic HSCT treatment in our center in the years 1998 to 2021 due to different hematologic pathologies (acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma, and others). Anemia was diagnosed in 13% of women and 35% of men. Anemia was most common in people after HSCT due to a history of acute myeloid leukemia (55% women, 30% men). In 56% of women and 17% of men, anemia was associated with chronic kidney disease. In patients with anemia, age was related to the eGFR (r = –0.39, p < 0.001), in patients without anemia age was negatively related to eGFR (r = –0.56, p < 0.001), and hemoglobin was positively related to platelet count ( r = 0.62, p < 0.001). Concluding, anemia, was relatively common in CKD after HSCT. In CKD, in particular with coexistent anemia, nephrology referral is to be taken into account to optimize therapy, including nephroprotection.

show abstract

Section: Discussionmentioning

confidence: 99%